Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

The U.S. Food and Drug Administration has revoked the emergency use authorization for four COVID-19 antibody-based drugs, ...

The Carroll County Community Foundation is pleased to announce the recipient of the 2025 Lilly Endowment Community ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...